SMMT FY 2022 Earnings — Summit Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

SMMTSummit Therapeutics Inc.

$12B

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$704,295-61.1% YoY

Gross Profit

-$2M-257.0% margin

Operating Income

-$60M-8467.0% margin

Net Income

-$79M-11185.9% margin

EPS (Diluted)

$-0.38

Cash Flow

Operating Cash Flow

-$42M

Free Cash Flow

-$42M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$664M

Total Liabilities

$538M

Stockholders' Equity

$127M

Cash & Equivalents

$349M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$704,295	$2M	-61.1%
Gross Profit	-$2M	$2M	-200.1%
Operating Income	-$60M	-$86M	+30.8%
Net Income	-$79M	-$89M	+11.1%